News Releases June 29, 2022 Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735 Read more June 1, 2022 Ventyx Biosciences to Participate in the Jefferies Healthcare Conference Read more May 12, 2022 Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Read more May 9, 2022 Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer Read more May 5, 2022 Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022 Read more March 23, 2022 Ventyx Biosciences Reports Full Year 2021 Financial Results and Highlights Recent Corporate Progress Read more March 7, 2022 Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference Read more December 6, 2021 Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis Read more November 19, 2021 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more November 17, 2021 Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update Read more First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page » Displaying 21 - 30 of 33
